Encorafenib and Binimetinib clinical trials

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

This study looks at two drugs, encorafenib and binimetinib, for people with a specific type of high-risk skin cancer called melanoma, after surgery. It aims to see if these drugs can stop the cancer from coming back, compared to standard check-ups.